NEC Reports Early TNBC Data and Expands NECVAX-NEO1 Trial

NEC said 5 of 8 patients achieved pCR in a Phase I/II trial of oral neoantigen therapy NECVAX-NEO1 with CPIs and chemotherapy. The company is expanding the trial to 28 patients, including U.S. sites after IND approval.